Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma

Publisher： Bentham Science Publishers

E-ISSN： 1875-6220|3|4|231-243

ISSN： 1570-1638

Source： Current Drug Discovery Technologies, Vol.3, Iss.4, 2006-12, pp. : 231-243

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Improving monoclonal antibody therapies in cancer

By  

Inpharma, Vol. 1, Iss. 1238, 2000-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody

By Camacho Luis H  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 3, 2008-03 ,pp. : 371-385

Informa Healthcare

Access to resources Recommend Favorite

Prognostic Significance of PUMA in Pancreatic Ductal Adenocarcinoma

By Du QH   Zhang KJ   Jiao XL   Zhao J   Zhang M   Yan BM   Xu YB  

The Journal of International Medical Research, Vol. 40, Iss. 6, 2012-11 ,pp. : 2066-2072

Field House Publishing

Access to resources Recommend Favorite

Rituximab and other emerging monoclonal antibody therapies for lymphoma

By Tobinai Kensei  

Expert Opinion on Emerging Drugs, Vol. 7, Iss. 2, 2002-10 ,pp. : 289-302

Informa Healthcare

Access to resources Recommend Favorite

The clinical application of monoclonal antibody therapies in renal transplantation

By Dhanireddy Kiran K   Xu He   Mannon Roslyn B   Hale Douglas A   Kirk Allan D  

Expert Opinion on Emerging Drugs, Vol. 9, Iss. 1, 2004-05 ,pp. : 23-37

Informa Healthcare

Access to resources Recommend Favorite